Dayan CM, Lecumberri B, Muller I, et al. Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies. Multiple Sclerosis Journal - Experimental, Translational and Clinical. 2023;9(1).
Ghiani, M.; Zhuleku, E.; Dillenseger, A.; Maywald, U.; Fuchs, A.; Wilke, T.; Ziemssen, T. Data Resource Profile: The Multiple Sclerosis Documentation System 3D and AOK PLUS Linked Database (MSDS-AOK PLUS). J. Clin. Med. 2023, 12, 1441.
Callegari I, Schneider M, Aebischer V, Voortman MM, Proschmann U, Ziemssen T, Lindberg R, Fischer-Barnicol B, Khalil M, Kappos L, Kuhle J, Sanderson NSR, Derfuss T. Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis. Ther Adv Neurol Disord. 2023 Jan 30;16:17562864221150040.
Masanneck L, Räuber S, Schroeter CB, Lehnerer S, Ziemssen T, et al. Driving time-based identification of gaps in specialised care coverage: An example of neuroinflammatory diseases in Germany. DIGITAL HEALTH. 2023;9.
Orschiedt J, Jacyshyn-Owen E, Kahn M, Jansen S, Joschko N, Eberl M, Schneeweiss S, Friedrich B, Ziemssen T. The influence of the COVID-19 pandemic on the prescription of multiple sclerosis medication in Germany. Biomed Pharmacother. 2023 Feb;158:114129.
Ziemssen T, Groth M, Ettle B, Bopp T. Immune Response to SARS-CoV-2 mRNA Vaccines in an Open-Label Multicenter Study in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab. Vaccines (Basel). 2022 Dec 16;10(12):2167.